These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 9199408)

  • 21. Tissue factor pathway inhibitor; its structure, function and clinical significance.
    Kato H
    Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solution structure of an isolated antibody VL domain.
    Constantine KL; Friedrichs MS; Metzler WJ; Wittekind M; Hensley P; Mueller L
    J Mol Biol; 1994 Feb; 236(1):310-27. PubMed ID: 8107112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor.
    Petersen LC; Bjørn SE; Olsen OH; Nordfang O; Norris F; Norris K
    Eur J Biochem; 1996 Jan; 235(1-2):310-6. PubMed ID: 8631347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kunitz-type soybean trypsin inhibitor revisited: refined structure of its complex with porcine trypsin reveals an insight into the interaction between a homologous inhibitor from Erythrina caffra and tissue-type plasminogen activator.
    Song HK; Suh SW
    J Mol Biol; 1998 Jan; 275(2):347-63. PubMed ID: 9466914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding.
    Piro O; Broze GJ
    Circulation; 2004 Dec; 110(23):3567-72. PubMed ID: 15557366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of the structure of oxidised Desulfovibrio africanus ferredoxin I by 1H NMR spectroscopy and comparison of its solution structure with its crystal structure.
    Davy SL; Osborne MJ; Moore GR
    J Mol Biol; 1998 Apr; 277(3):683-706. PubMed ID: 9533888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solution structure and dynamics of PEC-60, a protein of the Kazal type inhibitor family, determined by nuclear magnetic resonance spectroscopy.
    Liepinsh E; Berndt KD; Sillard R; Mutt V; Otting G
    J Mol Biol; 1994 May; 239(1):137-53. PubMed ID: 8196042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear magnetic resonance solution structure of dendrotoxin K from the venom of Dendroaspis polylepis polylepis.
    Berndt KD; Güntert P; Wüthrich K
    J Mol Biol; 1993 Dec; 234(3):735-50. PubMed ID: 8254670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure of human des(1-45) factor Xa at 2.2 A resolution.
    Padmanabhan K; Padmanabhan KP; Tulinsky A; Park CH; Bode W; Huber R; Blankenship DT; Cardin AD; Kisiel W
    J Mol Biol; 1993 Aug; 232(3):947-66. PubMed ID: 8355279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The solution structure of the Tyr41-->His mutant of the single-stranded DNA binding protein encoded by gene V of the filamentous bacteriophage M13.
    Folkers PJ; Nilges M; Folmer RH; Konings RN; Hilbers CW
    J Mol Biol; 1994 Feb; 236(1):229-46. PubMed ID: 8107108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-dimensional solution structure and backbone dynamics of a variant of human interleukin-3.
    Feng Y; Klein BK; McWherter CA
    J Mol Biol; 1996 Jun; 259(3):524-41. PubMed ID: 8676386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor.
    Lockett JM; Mast AE
    Biochemistry; 2002 Apr; 41(15):4989-97. PubMed ID: 11939795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of leukocyte elastase on tissue factor pathway inhibitor.
    Higuchi DA; Wun TC; Likert KM; Broze GJ
    Blood; 1992 Apr; 79(7):1712-9. PubMed ID: 1558967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factor Xa enhances the binding of tissue factor pathway inhibitor to acidic phospholipids.
    Valentin S; Schousboe I
    Thromb Haemost; 1996 May; 75(5):796-800. PubMed ID: 8725726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant tissue factor pathway inhibitor enhances the binding of factor Xa to human monocytes.
    Li A; Chang AC; Peer GT; Wun TC; Taylor FB
    Thromb Haemost; 2001 May; 85(5):830-6. PubMed ID: 11372676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor.
    Rao LV; Ruf W
    Biochemistry; 1995 Aug; 34(34):10867-71. PubMed ID: 7662667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain.
    Augustsson C; Svensson A; Kjaer B; Chao TY; Wenjuan X; Krogh BO; Breinholt J; Clausen JT; Hilden I; Petersen HH; Petersen LC
    J Thromb Haemost; 2018 May; 16(5):893-904. PubMed ID: 29532595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The lipoprotein-associated coagulation inhibitor.
    Broze GJ; Girard TJ; Novotny WF
    Prog Hemost Thromb; 1991; 10():243-68. PubMed ID: 2008533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amino acid sequence and carbohydrate structure of a recombinant human tissue factor pathway inhibitor expressed in Chinese hamster ovary cells: one N-and two O-linked carbohydrate chains are located between Kunitz domains 2 and 3 and one N-linked carbohydrate chain is in Kunitz domain 2.
    Nakahara Y; Miyata T; Hamuro T; Funatsu A; Miyagi M; Tsunasawa S; Kato H
    Biochemistry; 1996 May; 35(20):6450-9. PubMed ID: 8639592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution.
    Craescu CT; Rouvière N; Popescu A; Cerpolini E; Lebeau MC; Baulieu EE; Mispelter J
    Biochemistry; 1996 Aug; 35(34):11045-52. PubMed ID: 8780506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.